Micromet announced updated results from a Phase 2 trial of blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). This multi-center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results